A complex Polycomb issue: the two faces of EZH2 in cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In the April 1, 2012, issue of Genes & Development, Simon and colleagues (pp. 651–656) demonstrated that the disruption of Ezh2 in mice is sufficient to cause T-acute lymphoblastic leukemia (T-ALL). Moreover, in concert with concurrent studies, the authors revealed that similar mechanisms are involved in human T-ALL. These data contrast with previous findings showing that increased EZH2 activity promotes cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 3×
“All core components of PRC2 are strictly required for embryonic development, and their loss is usually lethal at the stage of gastrulation, when the basic body architecture is established (Simon and Kingston 2009; Margueron and Reinberg 2011).”
BackgroundThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 2×
“…26:751–755 2012 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/12; www.genesdev.org 751 mon solid tumor types, and high expression is associated with aggressive cases and progression (Varambally et al. 2002; Bracken et al. 2003), consistent with a straightforward role of EZH2 as an oncogene.”
BackgroundDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 1×
“Moreover, very recently, this residue was found to be subject to very distinct, recurrent mutations in three types of aggressive pediatric brain tumors (Schwartzentruber et al. 2012; Wu et al. 2012).”
BackgroundSt. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · cited 1×
“Moreover, inactivating mutations of EZH2 in MDSs and myelofibrosis (a subtype of MPD) predict poor survival (Bejar et al. 2011; Guglielmelli et al. 2011).”
BackgroundThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 5×
“(2012) unequivocally demonstrate that disruption of EZH2 is sufficient to cause T-ALL in mice, and three concurrent studies implicate PRC2 in human T-ALL (Ntziachristos et al. 2012; Simon et al. 2012; Zhang et al. 2012).”
BackgroundInfluentialBmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452 · cited 1×
“Specifically, loss of Bmi1 (PRC1) severely compromises stem cell function, while heterozygous loss of several PRC2 components was reported to enhance stem and progenitor cell activity (Lessard et al. 1999; Lessard and Sauvageau 2003; Majewski et al. 2010).”
BackgroundEZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 2×
“(Ernst et al. 2010; Makishima et al. 2010; Nikoloski et al. 2010).”
BackgroundTan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · cited 4×
“A small molecule, 3-deazaneplanocin A, that inhibits EZH2 by indirect mechanisms has been shown to interfere with the growth of many human tumor cell lines, but likely inhibits histone methylation very broadly (Tan et al. 2007).”
BackgroundInfluentialSomatic mutations of the histone H3K27 demethylase gene UTX in human cancer
van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.349 · Cited by 784
Agger, K., Cloos, P. A. C., Rudkjær, L., Williams, K., Andersen, G., Christensen, J., & Helin, K. (2009) · Genes & Development · doi:10.1101/gad.510809 · Cited by 427 · cited 6×
“The inves- 752 GENES & DEVELOPMENT tigators also demonstrated decreased expression of EZH2 and increased expression of JMJD3 (aka KDM6B), which (like decreased EZH2) should decrease H3K27me3 (Agger et al. 2009).”
BackgroundInfluentialPolycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling
Su, I.-H., Dobenecker, M.-W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., Viale, A., Reinberg, D., Wülfing, C., & Tarakhovsky, A. (2005) · Cell · doi:10.1016/j.cell.2005.02.029 · Cited by 365 · cited 1×
“Notably, however, there is a more stringent requirement for Ezh2 activity at distinct bottlenecks of differentiation, as loss of Ezh2 is associated with blocks in early B-cell and T-cell development (Su et al. 2005) that are ostensibly not compensated by Ezh1.”
BackgroundEzhkova, E., Lien, W.-H., Stokes, N., Pasolli, H. A., Silva, J. M., & Fuchs, E. (2011) · Genes & Development · doi:10.1101/gad.2019811 · Cited by 357
Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS
Barradas, M., Anderton, E., Acosta, J. C., Li, S., Banito, A., Rodriguez-Niedenführ, M., Maertens, G., Banck, M., Zhou, M.-M., Walsh, M. J., et al. (2009) · Genes & Development · doi:10.1101/gad.511109 · Cited by 352 · cited 2×
“In keeping with these findings, it was shown that the only other H3K27 demethylase, JMDJ3 (aka KDM6B), is also expressed at a lower than expected level in cancer (Agger et al. 2009; Barradas et al. 2009).”
BackgroundA key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Simon, C., Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S., Boucher, G., Chagnon, P., Drouin, S., Lambert, R., et al. (2012) · Genes & Development · doi:10.1101/gad.186411.111 · Cited by 264
Functional antagonism of the polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation
Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., & Sauvageau, G. (1999) · Genes & Development · doi:10.1101/gad.13.20.2691 · Cited by 219 · cited 2×
“In an early study, the Sauvageau group (Lessard et al. 1999) had reported that adult mice bearing a hypomorphic allele for the PRC2 component Eed developed severe lymphoid and myeloid disorders with aging.”
BackgroundNovel homo- and hemizygous mutations in EZH2 in myeloid malignancies
Makishima, H., Jankowska, A. M., Tiu, R. V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M. A., Putnam, P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.167 · Cited by 179 · cited 1×
“(Ernst et al. 2010; Makishima et al. 2010; Nikoloski et al. 2010).”
Score, J., Hidalgo-Curtis, C., Jones, A. V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., Stegelmann, F., Döhner, K., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367243 · Cited by 177
Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells
Majewski, I. J., Ritchie, M. E., Phipson, B., Corbin, J., Pakusch, M., Ebert, A., Busslinger, M., Koseki, H., Hu, Y., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2009-12-260760 · Cited by 135 · cited 1×
“Specifically, loss of Bmi1 (PRC1) severely compromises stem cell function, while heterozygous loss of several PRC2 components was reported to enhance stem and progenitor cell activity (Lessard et al. 1999; Lessard and Sauvageau 2003; Majewski et al. 2010).”
Background
Cited by
The interplay of histone modifications – writers that read
Zhang, T., Cooper, S., & Brockdorff, N. (2015) · EMBO reports · doi:10.15252/embr.201540945 · Cited by 804
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
Maze, I., Noh, K.-M., Soshnev, A. A., & Allis, C. D. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3673 · Cited by 349
Chang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Metadata
- Authors
- Hock, H.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-04-15
- Volume
- 26
- Issue
- 8
- Pages
- 751-755
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2102883893
- Cited by
- 121
- References
- 20
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.